Roivant Sciences Cash Flow Statement
ROIV / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Roivant Sciences used $765M in operating cash flow and negative free cash flow of $767M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | $4.3B | -$172.0M | $4.3B | -$809.2M | -$845.3M | -$809.2M |
| Depreciation & Amortization | $22.0M | $14.1M | $22.0M | - | $5.9M | - |
| Operating Cash Flow | -$765.3M | -$839.5M | -$765.3M | -$552.1M | -$677.7M | -$552.1M |
| Capital Expenditures | $1.4M | $4.6M | $1.4M | $5.8M | $17.4M | $5.8M |
| Free Cash Flow | -$766.6M | -$844.0M | -$766.6M | -$557.9M | -$695.2M | -$557.9M |
| Share Buybacks | - | $1.3B | $0 | - | - | - |
| FCF Margin | -2343.6% | -2905.2% | -2343.6% | -2344.8% | - | - |